drug
LINAGLIPTIN
Marketedupdated 3mo agoby Boehringer Ingelheim Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval24 co-mentions · 8 sources
- drugLINAGLIPTIN AND METFORMIN HYDROCHLORIDE20 co-mentions · 8 sources
- tagSmall Molecule12 co-mentions · 8 sources
- drugSITAGLIPTIN AND METFORMIN HYDROCHLORIDE8 co-mentions · 4 sources
- drugmetformin8 co-mentions · 4 sources
- drugmetformin hydrochloride8 co-mentions · 4 sources
- drugmetformin hydrochloride ER8 co-mentions · 4 sources
- drugmetformin hydrochloride SR8 co-mentions · 4 sources
indications
investigational
Type 2 Diabetes
all catalysts(4)
Trials studying LINAGLIPTIN
- phase4Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
- phase4Glycemic Variability of Combination Therapies in T2DM
- phase2A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
- phase2A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
- phase3Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus
- phase1Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets
- —Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus
- phase1To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 20, 2026
127 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (63)
- Dec 8, 2037patentUS 12364700*PED
- Dec 8, 2037patentUS 12364700*PED
- Dec 8, 2037patentUS 12364700*PED
- Dec 8, 2037patentUS 12364700*PED
- Jun 8, 2037method-of-use (U-4224)US 12364700
- Jun 8, 2037method-of-use (U-4224)US 12364700
- Jun 8, 2037method-of-use (U-4224)US 12364700
- Jun 8, 2037method-of-use (U-4224)US 12364700
- Sep 5, 2031patentUS 8853156*PED
- Mar 5, 2031formulationUS 88531564.6y
- Dec 4, 2030patentUS 8846695*PED4.3y
- Dec 4, 2030patentUS 8846695*PED4.3y
- Dec 4, 2030patentUS 8846695*PED4.3y
- Dec 4, 2030patentUS 8846695*PED4.3y
- Nov 21, 2030patentUS 9155705*PED4.3y
- Nov 21, 2030patentUS 9155705*PED4.3y
- Nov 21, 2030patentUS 9155705*PED4.3y
- Jun 4, 2030method-of-use (U-1503)US 88466953.8y
- Jun 4, 2030method-of-use (U-1503)US 88466953.8y
- May 21, 2030formulationUS 91557053.8y
- May 21, 2030formulationUS 91557053.8y
- May 21, 2030formulationUS 91557053.8y
- Apr 10, 2030method-of-use (U-3854)US 119113883.7y
- Apr 10, 2030method-of-use (U-3854)US 119113883.7y
- Apr 10, 2030method-of-use (U-3854)US 119113883.7y
- Apr 10, 2030method-of-use (U-3854)US 119113883.7y
- Feb 5, 2030patentUS 10034877*PED3.5y
- Feb 5, 2030patentUS 9486526*PED3.5y
- Oct 2, 2029patentUS 10022379*PED3.1y
- Oct 2, 2029patentUS 10022379*PED3.1y
- Oct 2, 2029patentUS 10022379*PED3.1y
- Oct 2, 2029patentUS 10973827*PED3.1y
- Oct 2, 2029patentUS 10973827*PED3.1y
- Oct 2, 2029patentUS 10973827*PED3.1y
- Oct 2, 2029patentUS 9415016*PED3.1y
- Oct 2, 2029patentUS 9415016*PED3.1y
- Oct 2, 2029patentUS 9415016*PED3.1y
- Aug 5, 2029method-of-use (U-2347)US 100348773.0y
- Aug 5, 2029method-of-use (U-1915)US 94865263.0y
- Apr 2, 2029method-of-use (U-2339)US 100223792.6y
- Apr 2, 2029method-of-use (U-2339)US 100223792.6y
- Apr 2, 2029method-of-use (U-2339)US 100223792.6y
- Apr 2, 2029formulationUS 109738272.6y
- Apr 2, 2029formulationUS 109738272.6y
- Apr 2, 2029formulationUS 109738272.6y
- Apr 2, 2029formulationUS 94150162.6y
- Apr 2, 2029formulationUS 94150162.6y
- Apr 2, 2029formulationUS 94150162.6y
- Nov 4, 2027patentUS 11033552*PED1.2y
- Nov 4, 2027patentUS 8673927*PED1.2y
- Nov 4, 2027patentUS 8673927*PED1.2y
- Nov 4, 2027patentUS 8673927*PED1.2y
- Nov 4, 2027patentUS 8673927*PED1.2y
- May 4, 2027formulationUS 11033552262d
- May 4, 2027formulationUS 12178819262d
- May 26, 2026patentUS 8883805*PED
- May 26, 2026patentUS 8883805*PED
- May 26, 2026patentUS 8883805*PED
- May 26, 2026patentUS 8883805*PED
- Nov 26, 2025formulationUS 8883805
- Nov 26, 2025formulationUS 8883805
- Nov 26, 2025formulationUS 8883805
- Nov 26, 2025formulationUS 8883805
FDA exclusivities (8)
- Dec 20, 2026PEDPediatric (6mo bonus)127d
- Dec 20, 2026PEDPediatric (6mo bonus)127d
- Dec 20, 2026PEDPediatric (6mo bonus)127d
- Dec 20, 2026PEDPediatric (6mo bonus)127d
- Jun 20, 2026M-295Method (3y)
- Jun 20, 2026M-295Method (3y)
- Jun 20, 2026M-295Method (3y)
- Jun 20, 2026M-295Method (3y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 28m ago
Found something off?
comments(0)
5-min edit window · permanent after that